लोड हो रहा है...
PD-1/PD-L1 Pathway Inhibitors in Advanced Prostate Cancer
INTRODUCTION: Pharmacological inhibition of immune checkpoint receptors or their ligands represents a transformative breakthrough in the management of multiple cancers. However, immune checkpoint inhibitors have yet to be FDA-approved for the management of metastatic prostate cancer (PCa), the commo...
में बचाया:
| में प्रकाशित: | Expert Rev Clin Pharmacol |
|---|---|
| मुख्य लेखकों: | , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
2018
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6317331/ https://ncbi.nlm.nih.gov/pubmed/29641940 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1464388 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|